Gilead Collaborates with Kyverna Therapeutics on T-cell Therapies
By Pratika Pahwa
Pharma Deals Review: Vol 2020 Issue 1 (Table of Contents)
Published: 31 Jan-2020
DOI: 10.3833/pdr.v2020.i1.2509 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Adding depth to its portfolio, Gilead has entered into a licensing agreement with Kyverna Therapeutics to develop T cell therapies for the treatment of autoimmune diseases...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS